Lupus & antiphospholipid syndrome
The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study
Authors' conclusion
Telitacicept is a potential treatment option for patients with SLE, especially in lupus nephritis, with significantly increased SRI-4 response rate and reduced the glucocorticoid and immunosuppressive drugs.
Study context
- Population
- Chinese patients with SLE receiving telitacicept for at least 4 weeks
- Outcome
- SRI-4 response
- Follow-up
- At least 4 weeks after first administration
Methodological detailsreal-life setting
- Real-life setting
Main finding
As reported in the abstract
after 4-45 weeks
Telitacicept
80%
16 events
Observational data: associations, not effects.
Further findings
Patients not receiving an immunosuppressive drug · endpoint
Mean
Before treatment
30.25 (95% CI 21.99–38.51) mg/d
After treatment
13.25 (95% CI 9.92–16.58) mg/d
IgM after treatment
- Cases with various reduction of IgM (p < 0.05)
- 19
- C3 and C4 stable or upward trend
24 h urinary protein in cases with baseline >0.5 g/d
- Cases with baseline 24 h urinary protein >0.5 g/d; median showed significant reduction
- 14
- Turned negative
- 7
Safety
Adverse events
- Mild to moderate and controllable
Original publication
The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study. Lupus. Published 23 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →